. "4"^^ . . . . "Does prostate re-biopsy have to include a biopsy of the transitional zone?"@en . . "Je nutn\u00E1 biopsie tranzicion\u00E1ln\u00ED z\u00F3ny p\u0159i rebiopsii prostaty?" . . "C\u00EDlem na\u0161\u00ED pr\u00E1ce bylo posoudit p\u0159esnou lokalizaci karcinomu prostaty u pacient\u016F, kte\u0159\u00ED podstoupili radik\u00E1ln\u00ED prostatektomii. N\u00E1sledn\u011B bychom cht\u011Bli navrhnout zm\u011Bnu strategie biopsie za \u00FA\u010Delem zv\u00FD\u0161en\u00ED jej\u00ED v\u00FDt\u011B\u017Enosti. Metody: V obdob\u00ED od kv\u011Btna 2008 do \u010Dervna 2011 bylo 33 prepar\u00E1t\u016F (23 po radik\u00E1ln\u00ED retropubick\u00E9 prostatektomii (RRP) a 10 po roboticky asistovan\u00E9 radik\u00E1ln\u00ED prostatektomii (RARP) vy\u0161et\u0159eno metodou histotopogram\u016F (whole mount sections). Lokalizace n\u00E1doru v nich byla n\u00E1sledn\u011B posouzena ve vztahu k McNealovu sch\u00E9matu zon\u00E1ln\u00ED anatomie prostaty. Ke statistick\u00E9mu vyhodnocen\u00ED byla pou\u017Eita metoda ch\u00ED-kvadr\u00E1t. V\u00FDsledky: Ve v\u0161ech p\u0159\u00EDpadech byl n\u00E1dor lokalizov\u00E1n v perifern\u00ED z\u00F3n\u011B prostaty (PZ). U 30% prepar\u00E1t\u016F byl v\u0161ak lokalizov\u00E1n z\u00E1rove\u0148 v tranzicion\u00E1ln\u00ED z\u00F3n\u011B (TZ), ani v jednom p\u0159\u00EDpad\u011B se v\u0161ak nejednalo o dominantn\u00ED n\u00E1dorov\u00E9 lo\u017Eisko. U p\u011Bti pacient\u016F (15 %) bylo v TZ p\u0159\u00EDtomno samostatn\u00E9 n\u00E1dorov\u00E9 lo\u017Eisko, to v\u0161ak progn\u00F3zu pacienta neovliv\u0148ovalo vzhledem k p\u0159\u00EDtomnosti dominantn\u00EDho tumoru v PZ. V 15 % p\u0159\u00EDpad\u016F do TZ infiltrovalo velkoobjemov\u00E9 n\u00E1dorov\u00E9 lo\u017Eisko z PZ. Ani u jednoho pacienta nebyl p\u0159\u00EDtomen tumor pouze v TZ. V p\u0159\u00EDpad\u011B, \u017Ee je tumor v prepar\u00E1tu lokalizov\u00E1n v TZ, jedn\u00E1 se v 60 % o lok\u00E1ln\u011B pokro\u010Dil\u00FD karcinom. Pokud je omezen jen na PZ, tumor je lok\u00E1ln\u011B pokro\u010Dil\u00FD jen v 13 % p\u0159\u00EDpad\u016F (statisticky signifikantn\u00ED rozd\u00EDl, p = 0,005). U tumor\u016F lokalizovan\u00FDch v TZ byla zaznamen\u00E1na ve vy\u0161\u0161\u00ED m\u00ED\u0159e biochemick\u00E1 recidiva po radik\u00E1ln\u00ED prostatektomii (u 50 % pacient\u016F), u tumor\u016F mimo TZ jen v 30 % p\u0159\u00EDpad\u016F. Tento rozd\u00EDl v\u0161ak nen\u00ED statisticky v\u00FDznamn\u00FD (p > 0,05). Z\u00E1v\u011Br: V po\u010D\u00E1te\u010Dn\u00EDm stadiu je karcinom prostaty lokalizov\u00E1n v\u017Edy v PZ. Je-li lokalizov\u00E1n v TZ, b\u00FDv\u00E1 to v\u017Edy se sou\u010Dasn\u011B p\u0159\u00EDtomn\u00FDm tumorem v PZ nebo to znamen\u00E1 jeho centr\u00E1ln\u00ED propagaci. Do PZ je tedy nutn\u00E9 nejprve zam\u011B\u0159it vpichy p\u0159i biopsii prostaty, podle na\u0161eho n\u00E1zoru v\u0161ak i p\u0159i rebiopsii. Biopsie TZ m\u00E1 sv\u00E9 m\u00EDsto v r\u00E1mci satura\u010Dn\u00ED biopsie a\u017E p\u0159i p\u0159etrv\u00E1vaj\u00EDc\u00EDm podez\u0159en\u00ED na karcinom i p\u0159es n\u011Bkolik negativn\u00EDch biopsii." . "[7D5AC989C26A]" . "2"^^ . "81722" . "\u010Cesk\u00E1 urologie" . "Does prostate re-biopsy have to include a biopsy of the transitional zone?"@en . . . "RIV/00098892:_____/13:#0000424" . . "C\u00EDlem na\u0161\u00ED pr\u00E1ce bylo posoudit p\u0159esnou lokalizaci karcinomu prostaty u pacient\u016F, kte\u0159\u00ED podstoupili radik\u00E1ln\u00ED prostatektomii. N\u00E1sledn\u011B bychom cht\u011Bli navrhnout zm\u011Bnu strategie biopsie za \u00FA\u010Delem zv\u00FD\u0161en\u00ED jej\u00ED v\u00FDt\u011B\u017Enosti. Metody: V obdob\u00ED od kv\u011Btna 2008 do \u010Dervna 2011 bylo 33 prepar\u00E1t\u016F (23 po radik\u00E1ln\u00ED retropubick\u00E9 prostatektomii (RRP) a 10 po roboticky asistovan\u00E9 radik\u00E1ln\u00ED prostatektomii (RARP) vy\u0161et\u0159eno metodou histotopogram\u016F (whole mount sections). Lokalizace n\u00E1doru v nich byla n\u00E1sledn\u011B posouzena ve vztahu k McNealovu sch\u00E9matu zon\u00E1ln\u00ED anatomie prostaty. Ke statistick\u00E9mu vyhodnocen\u00ED byla pou\u017Eita metoda ch\u00ED-kvadr\u00E1t. V\u00FDsledky: Ve v\u0161ech p\u0159\u00EDpadech byl n\u00E1dor lokalizov\u00E1n v perifern\u00ED z\u00F3n\u011B prostaty (PZ). U 30% prepar\u00E1t\u016F byl v\u0161ak lokalizov\u00E1n z\u00E1rove\u0148 v tranzicion\u00E1ln\u00ED z\u00F3n\u011B (TZ), ani v jednom p\u0159\u00EDpad\u011B se v\u0161ak nejednalo o dominantn\u00ED n\u00E1dorov\u00E9 lo\u017Eisko. U p\u011Bti pacient\u016F (15 %) bylo v TZ p\u0159\u00EDtomno samostatn\u00E9 n\u00E1dorov\u00E9 lo\u017Eisko, to v\u0161ak progn\u00F3zu pacienta neovliv\u0148ovalo vzhledem k p\u0159\u00EDtomnosti dominantn\u00EDho tumoru v PZ. V 15 % p\u0159\u00EDpad\u016F do TZ infiltrovalo velkoobjemov\u00E9 n\u00E1dorov\u00E9 lo\u017Eisko z PZ. Ani u jednoho pacienta nebyl p\u0159\u00EDtomen tumor pouze v TZ. V p\u0159\u00EDpad\u011B, \u017Ee je tumor v prepar\u00E1tu lokalizov\u00E1n v TZ, jedn\u00E1 se v 60 % o lok\u00E1ln\u011B pokro\u010Dil\u00FD karcinom. Pokud je omezen jen na PZ, tumor je lok\u00E1ln\u011B pokro\u010Dil\u00FD jen v 13 % p\u0159\u00EDpad\u016F (statisticky signifikantn\u00ED rozd\u00EDl, p = 0,005). U tumor\u016F lokalizovan\u00FDch v TZ byla zaznamen\u00E1na ve vy\u0161\u0161\u00ED m\u00ED\u0159e biochemick\u00E1 recidiva po radik\u00E1ln\u00ED prostatektomii (u 50 % pacient\u016F), u tumor\u016F mimo TZ jen v 30 % p\u0159\u00EDpad\u016F. Tento rozd\u00EDl v\u0161ak nen\u00ED statisticky v\u00FDznamn\u00FD (p > 0,05). Z\u00E1v\u011Br: V po\u010D\u00E1te\u010Dn\u00EDm stadiu je karcinom prostaty lokalizov\u00E1n v\u017Edy v PZ. Je-li lokalizov\u00E1n v TZ, b\u00FDv\u00E1 to v\u017Edy se sou\u010Dasn\u011B p\u0159\u00EDtomn\u00FDm tumorem v PZ nebo to znamen\u00E1 jeho centr\u00E1ln\u00ED propagaci. Do PZ je tedy nutn\u00E9 nejprve zam\u011B\u0159it vpichy p\u0159i biopsii prostaty, podle na\u0161eho n\u00E1zoru v\u0161ak i p\u0159i rebiopsii. Biopsie TZ m\u00E1 sv\u00E9 m\u00EDsto v r\u00E1mci satura\u010Dn\u00ED biopsie a\u017E p\u0159i p\u0159etrv\u00E1vaj\u00EDc\u00EDm podez\u0159en\u00ED na karcinom i p\u0159es n\u011Bkolik negativn\u00EDch biopsii."@cs . . "The aim of our study was to assess the precise tumour localization in radical prostatectomy specimens. Based on the study outcome, we are proposing a modification to the prostate biopsy strategy with the goal of increasing the tumour detection rate. Between May 2008 and June 2011 we evaluated whole mount section of 33 prostates (specimens were obtained by 23 radical retropubic and 10 robot-assisted radical prostatectomies). Tumour localization was assessed according to McNeal's prostate zonal anatomy scheme. Results:In all cases, the tumour was localized in the peripheral zone (PZ) of the prostate. In 30% of specimens a tumour was also found in the transitional zone (TZ). Neither of the TZ findings involved index tumours. In 15% of cases, separate tumour foci were found in the TZ, which did not affect the patient's prognosis. In the remaining 15% of cases, a large peripheral tumour infiltrated the TZ. In the case of tumours localized to the PZ, locally advanced prostate cancer was diagnosed in only 13% of the specimens (statistically significant difference, p = 0,005). In TZ tumours, PSA progression after radical prostatectomy was seen more frequently (in 50% of patients), in contrast to non-TZ tumours where progression developed in 30% of cases. This difference was found to be statistically insignificant (p > 0.05). Conclusion: During its early stages, prostate cancer is always localized in the PZ. In all cases where the tumour was found in the TZ locations, it was associated with a simultaneous PZ tumour focus or with a central progression of PZ tumour. It is therefore necessary to direct the biopsies into the PZ and we propose the use of a peripheral zone biopsy not only in the course of the initial biopsy, but also in the rebiopsy A TZ biopsy is indicated when a saturation biopsy is performed in cases where there is suspicion of prostate cancer due to PSA elevation above 10 ng/ml, in addition to repeated prostate biopsies with negative histology findings."@en . "I" . . "Je nutn\u00E1 biopsie tranzicion\u00E1ln\u00ED z\u00F3ny p\u0159i rebiopsii prostaty?" . "17" . . "8"^^ . "prostate carcinoma, PSA low level"@en . "RIV/00098892:_____/13:#0000424!RIV14-MZ0-00098892" . "CZ - \u010Cesk\u00E1 republika" . . "Ku\u010Derov\u00E1, Ladislava" . "Je nutn\u00E1 biopsie tranzicion\u00E1ln\u00ED z\u00F3ny p\u0159i rebiopsii prostaty?"@cs . "1211-8729" . "4" . . "Je nutn\u00E1 biopsie tranzicion\u00E1ln\u00ED z\u00F3ny p\u0159i rebiopsii prostaty?"@cs . . "\u0160tudent, Vladim\u00EDr" .